A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3820 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-12-23

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours

NCT05025969

Glioma

COMPLETED

Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

NCT06430424

Relapsed Cancer Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

RECRUITING

Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases

NCT02514915

Malignant Neoplasm Brain

COMPLETED NA

Deep Learning for Histopathological Classification and Prognostication of Gynaecologic Smooth Muscle Tumours

NCT06540846

Stump

RECRUITING

Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy

NCT02913534

Brain Metastasis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis. The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are expressed in human neuronal tissue and play an essential role in the physiology of development and function of the nervous system through activation by neurotrophins. Gene fusions involving NTRK genes lead to transcription of chimeric Trk proteins with constitutively activated or overexpressed kinase function conferring oncogenic potential. These genetic abnormalities have recently emerged as targets for cancer therapy, because novel compounds have been developed that are selective inhibitors of the constitutively active rearranged proteins. Developments in this field are being aided by next generation sequencing methods as tools for unbiased gene fusions discovery. However, the incidence of NTRK aberrations in solid tumors is unknown as well as the natural history of NTRK-rearranged tumors This study will provide better knowledge of NTRK gene fusion incidence to allow recommendations for pathological diagnosis.

Subjects who are tested positive by Immunohistochemistry (IHC : Pan-Trk IHC testing with mAb EPR17341) will be the subject of molecular assays such as next-generation sequencing (Archer Dx fusion assay) of tumor material \[parrafin embedded material\]), so that tumor harboring NTRK1, NTRK2 or NTRK3 gene fusions, is identified properly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects With Locally Advanced/Unresectable or Metastatic Solid Tumors

No intervention (this is a retrospective cohort study)

Intervention Type OTHER

No intervention (this is a retrospective cohort study) aimed at describing tumour samples. No treatment/intervention is being tested.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention (this is a retrospective cohort study)

No intervention (this is a retrospective cohort study) aimed at describing tumour samples. No treatment/intervention is being tested.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 1 month.
* Subject has/had a histologically or cytologically confirmed diagnosis of solid tumor including but not exclusively: soft tissue sarcoma, BRAF wild type melanoma, KRAS wild-type colorectal cancer, central nervous system, EGFR-wild type non-small cell lung cancer.
* Subject has locally advanced/unresectable or metastatic disease.
* Subject has received at least one systemic anti-cancer therapy for locally advanced/unresectable or metastatic disease for which there is available outcome information in terms of PFS, or the latter can be estimated based on the subject's records.
* Subject has tumor material available for immunoscreening (IHC for NTRK gene fusions).
* Written and voluntary informed consent understood, signed and dated, or a waiver of consent is granted according to French régulations.